Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Hiberix
- Generic Name
- Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
- DrugBank Accession Number
- DB10990
- Background
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752. These are heat inactivated and purified.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Toxoid - Synonyms
- Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
- Haemophilus influenzae type B-PRP and tetanus toxoid conjugate (PRP-T)
Pharmacology
- Indication
Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Haemophilus influenzae infections •••••••••••• •••••••••• ••••••• ••• •••••••• Prevention of Tetanus •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Hiberix Powder, for solution 10 mcg / 0.5 mL Intramuscular Glaxosmithkline Inc 2012-10-25 2023-04-12 Canada 
Hiberix Injection, powder, lyophilized, for solution 10 ug/0.5mL Intramuscular GlaxoSmithKline Biologicals SA 2009-08-24 2009-08-19 US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hiberix Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Water (1 mL/1mL) Injection, powder, for solution; Kit; Solution Intramuscular GlaxoSmithKline Biologicals SA 2023-12-20 Not applicable US Hiberix Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Water (1 mL/1mL) Injection, powder, for solution; Kit Intramuscular GlaxoSmithKline Biologicals SA 2015-12-21 Not applicable US Infanrix-ipv/hib Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (8 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 unit / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL) Suspension Intramuscular Glaxosmithkline Inc 2012-10-25 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ACT-HIB 0,5ML IM/SC 1 FLK LIYOFILIZE ASI+1 ENJ. COZUCU Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg/0.5mL) Powder, for solution Intramuscular; Subcutaneous 2015-02-03 Not applicable Turkey 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C9R35M8XV6
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Prevention Meningococcal Infections 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Tetanus 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Intramuscular; Subcutaneous 10 mcg/0.5mL Injection, powder, for solution Intramuscular 10 ug/0.5mL Injection, powder, for solution; kit Intramuscular Injection, powder, for solution; kit; solution Intramuscular Injection, powder, lyophilized, for solution Intramuscular 10 ug/0.5mL Powder, for solution Intramuscular 10 mcg / 0.5 mL Injection, powder, for solution Intramuscular 10 mcg/0.5ml Suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at April 30, 2023 03:04